Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.39 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.39 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.39 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CCR3 | P51677 | 6/20 | 0.49 |
| ▸ | DRD4 | P21917 | 5/20 | 0.44 |
| ▸ | CCR1 | P32246 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL2497171 | 1.00 | ALDH1A1 (0.50) | ALDH1A1CCR3DRD4CCR1HPGD | |
| SCHEMBL1809259 | 0.99 | ALDH1A1 (0.51) | ALDH1A1CCR3DRD4CCR1HPGD | |
| SCHEMBL1809253 | 0.99 | ALDH1A1 (0.51) | ALDH1A1CCR3DRD4CCR1HPGD | |
| Potassium SCHEMBL2497166 | 0.99 | ALDH1A1 (0.51) | ALDH1A1CCR3DRD4CCR1HPGD | |
| SCHEMBL2497161 | 0.98 | ALDH1A1 (0.50) | ALDH1A1CCR3DRD4CCR1HPGD | |
| SCHEMBL1811851 | 0.94 | ALDH1A1 (0.50) | ALDH1A1CCR3DRD4CCR1HPGD | |
| SCHEMBL1811845 | 0.94 | ALDH1A1 (0.50) | ALDH1A1CCR3DRD4CCR1HPGD | |
| SCHEMBL1811585 | 0.93 | ALDH1A1 (0.48) | ALDH1A1CCR3DRD4CCR1HPGD | |
| SCHEMBL1811580 | 0.93 | ALDH1A1 (0.48) | ALDH1A1CCR3DRD4CCR1HPGD | |
| SCHEMBL1812508 | 0.92 | ALDH1A1 (0.49) | ALDH1A1CCR3DRD4CCR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10130634-B2 | Therapeutic agent for ophthalmic disease | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-11-20 | — | — | US | claimed |
| EP-2042499-B1 | SALT OF A MORPHOLINE COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-06-27 | — | — | EP | claimed |
| US-20160193217-A1 | THERAPEUTIC AGENT FOR OPHTHALMIC DISEASE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-07-07 | — | — | US | claimed |
| US-8030303-B2 | Salt of morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-04 | — | — | US | claimed |
| US-20090264430-A1 | Salt of morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-22 | — | — | US | claimed |
| EP-2042499-A1 | SALT OF MORPHOLINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-04-01 | — | — | EP | claimed |
| US-20230312697-A1 | METHODS OF IMPROVING RETINA-ASSOCIATED DISEASE OUTCOME USING CCR3-INHIBITORS | ALKAHEST INC. | 2023-10-05 | — | — | US | disclosed |
| EP-4164643-A1 | METHODS OF IMPROVING RETINA-ASSOCIATED DISEASE OUTCOME USING CCR3-INHIBITORS | Alkahest, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| CN-115697334-A | Methods of improving retinal related disease outcomes using CCR3 inhibitors | 万能溶剂有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021252647-A1 | METHODS OF IMPROVING RETINA-ASSOCIATED DISEASE OUTCOME USING CCR3-INHIBITORS | ALKAHEST INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-10130634-B2 | Therapeutic agent for ophthalmic disease | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-11-20 | — | — | US | disclosed |
| EP-2042499-B1 | SALT OF A MORPHOLINE COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-06-27 | — | — | EP | disclosed |
| US-20160193217-A1 | THERAPEUTIC AGENT FOR OPHTHALMIC DISEASE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-07-07 | — | — | US | disclosed |
| US-8030303-B2 | Salt of morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-04 | — | — | US | disclosed |
| US-8030303-B2 | Salt of morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20090264430-A1 | Salt of morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264430-A1 | Salt of morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-2042499-A1 | SALT OF MORPHOLINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-04-01 | — | — | EP | disclosed |
| EP-2042499-A1 | SALT OF MORPHOLINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312697-A1 | METHODS OF IMPROVING RETINA-ASSOCIATED DISEASE OUTCOME USING CCR3-INHIBITORS | CCR3, CCR1, CCRL2 | HTR1A 2569/4885ADRA2A 2322/4885ADRA2B 1691/4885 |
| US-20090264430-A1 | Salt of morpholine compound | SLC11A2, SLC16A7, AVPR2 | HTR1A 2262/4885ADRA2A 1351/4885ADRA2B 701/4885 |
| US-10130634-B2 | Therapeutic agent for ophthalmic disease | MITF, UACA, VEGFA | HTR1A 1669/4885ADRA2A 1365/4885ADRA2B 1234/4885 |
| US-20160193217-A1 | THERAPEUTIC AGENT FOR OPHTHALMIC DISEASE | MITF, UACA, VEGFA | HTR1A 1669/4885ADRA2A 1365/4885ADRA2B 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.